Cisco (NASDAQ:CSCO): Pacific Crest thinks that Cisco is in good shape to hit an EPS of $3 in the medium term, and believes that the valuation appears overly bearish. It keeps an Outperform rating on the shares.
Biogen (NASDAQ:BIIB): Stifel believes that Biogen stock should be purchased on weakness, prior to the Q2 Tecfidera data. Continued strength in Tecfidera will cause analysts to push their estimates higher, and the firm keeps a Buy rating on the shares.
Dendreon (NASDAQ:DNDN): Despite dismal Q1 results, RW Baird would not be surprised to see a near term trading opportunity open up since management remained positive on future growth prospects. It keeps a Neutral on the shares, and a $6 price target.